{
    "nct_id": "NCT03719105",
    "official_title": "Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma/Leukemia in Children, Adolescents and Young Adults; A NK/T-Cell Lymphoma/Leukemia Consortium Study",
    "inclusion_criteria": "* Patients must weigh at least 10 kilograms at the time of the study enrollment.\n* Diagnosis\n\nNewly diagnosed patients with histologically proven mature T- and NK- cell neoplasms:\n\nCOHORT 1\n\n* Aggressive NK cell leukemia (ICD-O code 9948/3)\n* Extranodal NK/T-cell lymphoma, nasal type (ICD-O code 9719/3) COHORT 2\n* Enteropathy-associated T-cell lymphoma (ICD-O code 9717/3)\n* Hepatosplenic T-cell lymphoma (ICD-O code 9716/3)\n* Peripheral T-cell lymphoma, non-otherwise specified (ICD-O code 9702/3)\n* Angioimmunoblastic T-cell lymphoma (ICD-O code 9705/3)\n* Other mature T- and NK-cell neoplasm histologies will considered after case-by-case discussion with Study Chairs and executive Vice-Chair Patients with lymphoma must have stage III or IV disease (See Appendix III for Staging).\n\n  * Organ Function Requirements\n\nAdequate liver function defined as:\n\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age.\n* ALT (SGPT) < 3 x ULN for age.\n\nAdequate cardiac function defined as:\n\n* Shortening fraction of ≥ 27% by echocardiogram, or\n* Ejection fraction of ≥ 50% by radionuclide angiogram.\n\nAdequate pulmonary function defined as:\n\n• Patients with a history of pulmonary dysfunction must have no evidence of dyspnea at rest, no exercise intolerance due to pulmonary insufficiency, and a pulse oximetry > 92% while breathing room air unless current dysfunction is due to the lymphoma, in which case the patient is eligible.\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 31 Years",
    "exclusion_criteria": "* Alk+ or Alk- Anaplastic Large Cell Lymphoma (ALCL)\n* Patients with active CNS disease.\n* Patients with stage I or stage II disease (See Appendix III for Staging).\n* Patients who have received any prior cytotoxic chemotherapy for the current diagnosis of NHL.\n* Previous steroid treatment and/or radiation treatment are not allowed unless they are used for emergency management. Patients who have received emergency irradiation and/or steroid therapy will be eligible only if started on protocol therapy not more than one week from the start of radiotherapy or steroids.\n* Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarchal.\n* Lactating females, unless they have agreed not to breastfeed their infants.\n* Patients with Down syndrome.\n* Patients taking CYP3A4 substrates with narrow therapeutic indices. Patients (COHORT 2 ONLY) chronically receiving medications known to be metabolized by CYP3A4 and with narrow therapeutic indices (See Appendix V). The topical use of these medications (if applicable) is allowed.\n* Patients taking CYP3A4 inhibitors. Patients (COHORT 2 ONLY) chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment (See Appendix V). The topical use of these medications (if applicable) is allowed.\n* Patients taking CYP3A4 inducers. Patients (COHORT 2 ONLY) chronically receiving drugs that are known potent CYP3A4 inducers within 12 days prior to study enrollment (See Appendix V).",
    "miscellaneous_criteria": ""
}